B-Cell Lymphomas Coverage from Every Angle
Advertisement
Advertisement

Recent News

CAR T-Cell Therapy Versus Previous Standard of Care for Refractory Aggressive LBCL
ESMO 2022: Novel Antibody-Drug Conjugate Under Study in B-Cell Lymphoma
ESMO 2022: Role of ctDNA in Chinese Patients With Diffuse Large B-Cell Lymphoma
Use of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma
ESMO 2022: Can Machine Learning–Based Model Predict DLBCL Subtypes From Whole-Slide Images?
Prognostic Model May Help to Identify Elderly Patients With DLBCL Suited for Chemotherapy
Adding Bortezomib to Standard Treatment in Resistant DLBCL: Final Results From Phase II Trial
Safety and Efficacy of Blinatumomab for Patients With High-Risk DLBCL
BRUIN MCL-321 Focuses on Pirtobrutinib in BTK Inhibitor–Naive Mantle Cell Lymphoma
Zanubrutinib Plus Rituximab: Effective Alternative to R-CHOP in Elderly Patients With DLBCL?
Outcomes After BTK Inhibition in Mantle Cell Lymphoma: View From the United States and Japan
FDA Accepts sBLA for Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Induction Regimens for Older Patients With Mantle Cell Lymphoma
Survey of Oncologists and Hematologists: Considerations in Third-Line Treatment of Follicular Lymphoma
MSI2: Is This RNA-Binding Protein a Potential Therapeutic Target in Mantle Cell Lymphoma?
Pan Pacific 2022: POLARIX Trial of Polatuzumab Vedotin–Based Regimen in DLBCL
Primary Mediastinal LBCL: Closer Look at the Genetic Landscape
Phase II FLUORO Study to Evaluate Obinutuzumab Plus Atezolizumab in Follicular Lymphoma
Pan Pacific 2022: Early-Phase Study of Pirtobrutinib in Mantle Cell Lymphoma
Potential New Paradigm in the Diagnosis of Pediatric-Type Follicular Lymphoma
Ongoing Trial Aims to Study Efineptakin Alfa After Tisagenlecleucel Therapy for LBCL
Update on Brexucabtagene Autoleucel in the Treatment of Resistant Mantle Cell Lymphoma
Comparison of Two Different Chemotherapy Regimens for High-Risk Burkitt Lymphoma
Genetic and Molecular Profiling of Primary Mediastinal LBCL Identifies Probable Pathogenesis
Measurable Residual Disease–Driven, Time-Limited Treatment of Indolent Mantle Cell Lymphoma
Axicabtagene Ciloleucel Outcomes in LBCL Stratified by Ethnicity and Race
Updated Trial Data on Tazemetostat-Based Regimen in Follicular Lymphoma
Priority Review Granted by FDA for Mosunetuzumab in Follicular Lymphoma
Phase III Study to Evaluate Tafasitamab-cxix–Based Therapy for Advanced B-Cell Lymphoma
ASCO 2022: Novel CAR T-Cell Therapy Targets CD20 in Treatment of B-Cell Malignancies
Lisocabtagene Maraleucel Approved by FDA in Second-Line Treatment of LBCL
ASCO 2022: Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Follicular Lymphoma
After CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma: What’s Next?
EHA 2022: Patient-Reported Outcomes With Lisocabtagene Maraleucel in LBCL
ASCO 2022: Influence of Racial Identity on Survival Outcomes in DLBCL
EHA 2022: Preliminary Data From PACIFIC Trial of Nivolumab Plus Brentuximab Vedotin in LBLC
EHA 2022: Fixed Duration of Bispecific Antibody Glofitamab in Resistant DLBCL
ASCO 2022: 3-Year Follow-Up From ZUMA-2 Trial of KTE-X19 in Resistant Mantle Cell Lymphoma
Utility of Routinely Collected Geriatric Assessment in Patients With DLBCL
ASCO 2022: Intermittent Dosing of Zandelisib in Resistant Follicular Lymphoma
FDA Withdraws Approval of Umbralisib for Treatment of Lymphomas Over Safety Concerns
ASCO 2022: Ibrutinib Plus Chemoimmunotherapy in Older Patients With Mantle Cell Lymphoma
FDA Grants Approval to Tisagenlecleucel for Treatment of Resistant Follicular Lymphoma
Risk of COVID-19 Breakthrough Infections in Vaccinated Patients With Hematologic Cancer
BTK Inhibitor Zanubrutinib Under Study in the Treatment of Resistant DLBCL
Phase II ZUMA-12 Trial Evaluates First-Line Use of Axicabtagene Ciloleucel in High-Risk LBCL
Predicting Remission With CAR T-Cell Therapy in Large B-Cell Lymphoma: Focus on FDG-PET Imaging
CD20-CD3 Bispecific Antibody Under Study in Resistant B-Cell Non-Hodgkin Lymphoma
Can ctDNA Analysis Be Used to Predict Outcomes in High-Risk DLBCL?
AKT Inhibitor Capivasertib Focus of Phase II Trial in B-Cell NHL
AACR 2022: Investigational BCL2 Inhibitors Demonstrate Varying Levels of Antilymphoma Activity
AACR 2022: Pharmacologic Attributes of Axicabtagene Ciloleucel and Therapeutic Index in Lymphoma
AACR 2022: Novel Microtubule-Targeting Agent Demonstrates Antilymphoma Activity
AACR 2022: Can BCL2 Family Protein Dephosphorylation Resensitize Venetoclax-Induced Apoptosis?
AACR 2022: Impact of PRMT5 Inhibition on BH3 Mimetic Sensitivity in Mantle Cell Lymphoma
AACR 2022: Predicting Response/Resistance to Brexucabtagene Autoleucel in Mantle Cell Lymphoma
AACR 2022: Can Decitabine Sensitize DLBCL Cells to Venetoclax?
Adding EP4 Receptor Agonists to CD20 Antigen Therapy in B-Cell Malignancies
Axicabtagene Ciloleucel Receives FDA Approval in Large B-Cell Lymphoma


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.